U.S. markets close in 32 minutes

Nevro Corp. (NVRO)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
165.99-4.92 (-2.88%)
As of 3:28PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close170.91
Open171.05
Bid165.22 x 900
Ask165.76 x 800
Day's Range161.86 - 173.50
52 Week Range65.05 - 188.14
Volume433,744
Avg. Volume374,326
Market Cap5.715B
Beta (5Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)-2.73
Earnings DateMay 05, 2021 - May 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est194.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Nevro Corp (NVRO) Q4 2020 Earnings Call Transcript
    Motley Fool

    Nevro Corp (NVRO) Q4 2020 Earnings Call Transcript

    NVRO earnings call for the period ending December 31, 2020.

  • Benzinga

    Recap: Nevro Q4 Earnings

    Shares of Nevro (NYSE:NVRO) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 52.27% year over year to ($0.21), which beat the estimate of ($0.33). Revenue of $109,731,000 declined by 4.06% from the same period last year, which beat the estimate of $107,430,000. Guidance Nevro Sees Q1 Sales Of $84M-$86M Vs $94.23M Estimates Conference Call Details Date: Feb 24, 2021 Time: 04:30 PM View more earnings on NVRO ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwww.nevro.com%2F&eventid=2944669&sessionid=1&key=F528C36580B0D45AEC91FD0917977737®Tag=&V2=false&sourcepage=register Technicals Company's 52-week high was at $188.14 Company's 52-week low was at $65.05 Price action over last quarter: Up 6.73% Company Profile Nevro Corp is a medical device company. Its key product is the Senza spinal cord stimulation system, a neuromodulation platform for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. Nevro generates the majority of its revenue in the United States. It also receives nearly half of its revenue from Australia, the United Kingdom, and Germany. See more from BenzingaClick here for options trades from BenzingaNetApp: Q3 Earnings InsightsFidelity National Finl: Q4 Earnings Insights© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Nevro Reports Fourth Quarter and Full Year 2020 Financial Results
    PR Newswire

    Nevro Reports Fourth Quarter and Full Year 2020 Financial Results

    Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full year ended December 31, 2020 and provided 2021 guidance.